Company Filing History:
4 out of 1,035 
2 out of 4,443 
2 out of 15 Years Active: 2008-2023
Title: The Innovative Contributions of Jeremy Graff
Introduction
Jeremy Graff is a notable inventor based in Indianapolis, IN (US), recognized for his significant contributions to the field of immunotherapy. With a total of 7 patents to his name, Graff has made strides in optimizing treatment strategies that enhance patient outcomes.
Latest Patents
One of Graff's latest patents focuses on "Beta glucan immunopharmacodynamics." This disclosure provides dosing strategies for soluble β-glucan immunotherapy to optimize acute immunopharmacodynamic responses. It also outlines a method for analyzing a sample from a subject to identify the appropriate dosing strategy for this immunotherapy. The method includes obtaining a biological sample, analyzing it for a biomarker, and classifying the subject based on the biomarker levels.
Another significant patent involves "β-glucan methods and compositions that affect the tumor microenvironment." This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents. These agents promote an immunostimulatory environment, enhancing the effectiveness of anti-angiogenics and checkpoint inhibitors.
Career Highlights
Throughout his career, Jeremy Graff has worked with prominent companies such as Isis Pharmaceuticals, Inc. and Eli Lilly and Company. His experience in these organizations has contributed to his expertise in the field of immunotherapy and drug development.
Collaborations
Graff has collaborated with notable colleagues, including Kenneth W. Dobie and Eric G. Marcusson. These partnerships have further enriched his work and innovations in the field.
Conclusion
Jeremy Graff's innovative contributions to immunotherapy demonstrate his commitment to advancing medical science. His patents and collaborations reflect a dedication to improving treatment strategies for patients.